Early alterations of adrenergic cardiac function in Parkinson's disease;Alteración precoz de la función adrenérgica cardíaca en la enfermedad de Parkinson

Neurologia

Volumn 19, Issue 2, 2004, Pages 53-58

  Campos, Victor M ^a   Rebollo, A C ^a   Jimenez Hoyuela J M ^a   Gomez Doblas J J ^a   Medialdea, P ^a   Vila, E ^a   Gutierrez Hurtado A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Autonomic function; Heart scintigraphy; Metaiodobenzylguanidine; Parkinson's disease; Sympathetic nervous system

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART; HEART SCINTISCANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; PARKINSON DISEASE; SYMPATHETIC FUNCTION;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RADIOPHARMACEUTICALS; SYMPATHETIC NERVOUS SYSTEM;

EID: 1642410832     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy Body diseases. Neurology 1999;52:1269-71.
2. Kuzuhara S, Yoshimura M. Clinical and neuropathological aspects of diffuse Lewy body disease in the elderly. Adv Neurol 1993;60:464-9.
3. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an inmmunohistochemical study of Lewy body-containing neurons in teh enteric nervous system. Acta Neuropathol (Ber) 1990;79:581-3.
4. Poewe W. The clinical spectrum of Lewy body disorders. En: Tolosa E, Shultz JB, McKeith IG, Ferrer I, editores. Neurodegenerative disorders associated with alfa-synuclein pathology. Barcelona: Ars Medica, 2002; p. 73-82.
5. Xu J, Kao S-Y, Lee FJ, Song W, Jin L-W, Yankner BA. Dopamine-dependent neurotoxicity of alfa-sinuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002;8:600-6.
6. Ludin SM, Steiger UH, Ludin HP. Autonomic disturbances and cardiovascular reflexes in idiopathic Parkinson disease. Arch Neurol 1987;235:10-5.
7. Merlet P, Vallete H, Bubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Pronostic value of cardiac metaiodobenzylguanidine imagen in patients with heart failure. J Nucl Med 1992;33:471-7.
8. Sisson JC. The adrenergic nervous system of the heart and nuclear medicine. En: Freeman LM, editor. Nuclear Medicine Annual 1993. New York: Raven Press, 1993; p. 233-57.
9. Matheja P, Schäfers M, Weckesser M, Wichter T, Schober O. Imaging sympathetic innervation. Q J Nucl Med 1999;43:281-90.
10. Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med 2000;27:1-6.
11. 123-MIBG myocardial sympathetic innervation scintigraphy and Parkinson's disease. World J Nucl Med 2002;1(Suppl 2):213.
12. Gibb WRG, Lees AJ. The relevance ot the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
13. Hoehn MM, Yahr MD. Parkinsonism: progression and mortality. Neurology 1967;17:427-42.
14. Chaudhuri KR. Autonomic dysfunction in movement disorders. Curr Opin Neurol 2001;14:505-11.
15. Schäfers M, Schober O, Lerch H. Cardiac sympathetic neurotransmission scintigraphy. Eur J Nucl Med 1998;25:435-41.
16. Langer O, Halldin C. PET and SPET tracers for mapping the cardiac nervous system. Eur J Nucl Med 2002;29:416-34.
17. 123I-metaoidobenzylguanidine in Parkinson's disease. Nucl Med Commun 1998;19:137-42.
18. 123]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999;53:1020-5.
19. 123I-MIBG uptake in Parkinson's disease. Acta Neurol Scand 1998;97:303-6.
20. 123I-MIBG uptake by the heart in Parkinson's disease: assesment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999;40:371-5.
21. 123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 1994;49:81-4.
22. Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without authonomic failure is heart selective and disease especific. Eur J Nucl Med 2000;27:566-73.
23. Takatsu H, Nagashima K, Murase M, Fujiwara H, Nishida H, Matsuo H, et al. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 2000;248:44-5.
24. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;76:189-94.
25. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.
26. 123I-MIBG-SPECT. J Neurol Sci 2000;175:3-12.
27. Goldstein DS, Holmes C, Cannon III RO, Eisenhofer G, Kopin IJ. Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 1997;336:696-702.
28. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon III RO. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000;133:338-47.
29. Campos V, Jiménez-Hoyuela JM, Rebollo A, Medialdea P, Rius F. Función simpática cardíaca y enfermedad de Parkinson: análisis de 60 casos. Neurologia 2002;17:579-80.
30. Serrano V, Gutiérrez A, Jiménez-Hoyuela JM, Rebollo A, Gómez-Doblas JJ, Campos V. Captación miocárdica de MIBG en la enfermedad por cuerpos de Lewy difusos. Neurologia 2002;17:579.
31. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 metaiodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998;155:60-7.
32. Wenning GK, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-47.